Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia-Reference-Cited by-同舟云学术

Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia

Published:2014-02-05 Issue:7 Volume:28 Page:1545-1548
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Matsuda K,Nakazawa Y^ORCID,Iwashita C,Kurata T,Hirabayashi K,Saito S,Tanaka M,Yoshikawa K,Yanagisawa R,Sakashita K,Sasaki S,Honda T,Koike K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201458.pdf

Reference14 articles.

1. Koike K, Matsuda K . Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 2008; 141: 567–575.

2. Loh ML . Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 2011; 152: 677–687.

3. Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013; 45: 937–941.

4. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18–24.

5. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013; 27: 1401–1403.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to chemotherapy in juvenile myelomonocytic leukemia and its clinical implications for survival: A retrospective registry-based study of the Korean Pediatric Hematology-Oncology Group;Leukemia Research;2023-06

2. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia;Haematologica;2020-12-30

3. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia;British Journal of Haematology;2019-06-20

4. Panobinostat inhibits the proliferation of CD34+ CD38− cells under stimulation of hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia;Pediatric Blood & Cancer;2018-07-16

5. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study;Pediatric Blood & Cancer;2018-03-12